Published in J Dtsch Dermatol Ges on April 10, 2013
Omalizumab in recurring larynx angioedema: a case report. Asia Pac Allergy (2014) 0.75
Efficacy of Omalizumab in a Patient with Angioedema Clinically Resembling a Hereditary Angioedema. Ann Dermatol (2016) 0.75
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol (2011) 2.29
More on PML in Patients Treated with Dimethyl Fumarate. N Engl J Med (2016) 1.73
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (2009) 1.51
Case reports of PML in patients treated for psoriasis. N Engl J Med (2013) 1.45
The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol (2004) 1.35
Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol (2008) 1.32
Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum (2005) 1.31
Role of food allergy in atopic dermatitis. Curr Opin Allergy Clin Immunol (2004) 1.27
Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Derm Venereol (2010) 1.27
Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factors. J Invest Dermatol (2009) 1.26
Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology (2014) 1.25
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges (2012) 1.25
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study. Carcinogenesis (2005) 1.09
Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccination. J Am Acad Dermatol (2005) 1.03
Ustekinumab. Nat Rev Drug Discov (2009) 1.02
The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol (2011) 0.99
Screening for biomarkers of spermatogonia within the human testis: a whole genome approach. Hum Reprod (2010) 0.98
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med (2015) 0.98
[S3-guidelines for the treatment of psoriasis vulgaris Update 2011]. J Dtsch Dermatol Ges (2011) 0.96
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol (2011) 0.95
Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol (2005) 0.95
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol (2010) 0.94
Expression of activation-induced, T cell-derived, and chemokine-related cytokine/lymphotactin and its functional role in rheumatoid arthritis. Arthritis Rheum (2003) 0.93
Scalp psoriasis. J Dtsch Dermatol Ges (2011) 0.91
Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol (2011) 0.91
Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol (2008) 0.90
Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany: a multi-center study. J Dtsch Dermatol Ges (2007) 0.90
Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic inflammatory reactions. J Allergy Clin Immunol (2002) 0.89
German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges (2014) 0.89
Staphylococcus aureus-derived enterotoxins enhance house dust mite-induced patch test reactions in atopic dermatitis. Exp Dermatol (2007) 0.88
Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol (2002) 0.88
Rational for statin use in psoriatic patients. Arch Dermatol Res (2013) 0.88
National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Arch Dermatol Res (2013) 0.87
Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res (2006) 0.87
The multi-step process of human skin carcinogenesis: a role for p53, cyclin D1, hTERT, p16, and TSP-1. Eur J Cell Biol (2007) 0.86
Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges (2007) 0.86
Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res (2008) 0.85
[S3-Guidelines for the therapy of psoriasis vulgaris]. J Dtsch Dermatol Ges (2006) 0.85
Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations. J Drugs Dermatol (2008) 0.84
Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). Arch Dermatol Res (2014) 0.84
Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol (2008) 0.84
Psoriasis--new insights into pathogenesis and treatment. Dtsch Arztebl Int (2009) 0.84
Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol (2007) 0.83
No association between three xeroderma pigmentosum group C and one group G gene polymorphisms and risk of cutaneous melanoma. Eur J Hum Genet (2005) 0.83
Therapy of psoriasis in childhood and adolescence - a German expert consensus. J Dtsch Dermatol Ges (2011) 0.83
Cyclosporine therapy in dermatology. J Dtsch Dermatol Ges (2009) 0.83
Anxiety, depression and impaired health-related quality of life in patients with occupational hand eczema. Contact Dermatitis (2012) 0.82
Cytokine gene polymorphisms in allergic contact dermatitis. Contact Dermatitis (2003) 0.82
No association of vitamin D metabolism-related polymorphisms and melanoma risk as well as melanoma prognosis: a case-control study. Arch Dermatol Res (2012) 0.81
Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Relat Outcome Meas (2010) 0.80
How do regional factors influence psoriasis patient care in Germany? J Dtsch Dermatol Ges (2010) 0.80
[The role of biologics into the management of psoriasis: a consensus paper by the Psoriasis Study Group, Arbeitsgemeinschaft Dermatologische Forschung]. J Dtsch Dermatol Ges (2003) 0.80
Variations in the peroxisome proliferator-activated receptor-gamma gene and melanoma risk. Cancer Lett (2006) 0.80
Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis. N Engl J Med (2012) 0.80
[15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris]. J Dtsch Dermatol Ges (2009) 0.80
CD40 ligation during dendritic cell maturation reduces cell death and prevents interleukin-10-induced regression to macrophage-like monocytes. Exp Dermatol (2007) 0.79
Genetic factors in contact allergy--review and future goals. Contact Dermatitis (2011) 0.79
Use of fumaric acid esters in psoriasis. Indian J Dermatol Venereol Leprol (2007) 0.79
Quality of psoriasis care in Germany--results of the national study PsoHealth 2007. J Dtsch Dermatol Ges (2008) 0.78
Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol (2010) 0.78
Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab. Curr Probl Dermatol (2009) 0.78
[Psoriasis--clinical picture and current therapy]. Med Monatsschr Pharm (2009) 0.78
Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges (2014) 0.77
Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis. J Dermatol Sci (2009) 0.77
Variations in the genes encoding the peroxisome proliferator-activated receptors alpha and gamma in psoriasis. Arch Dermatol Res (2004) 0.77
Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Dermatology (2015) 0.77
Drug supply for children with psoriasis in Germany. J Dtsch Dermatol Ges (2013) 0.76
A prospective, rater-blind, randomized comparison of the effectiveness and tolerability of Belotero ® Basic versus Restylane ® for correction of nasolabial folds. Eur J Dermatol (2010) 0.76
Systemic treatment with corticosteroids in psoriasis--health care provision far beyond the S3-guidelines. J Dtsch Dermatol Ges (2011) 0.76
Analysis of a functional serotonin transporter promoter polymorphism in psoriasis vulgaris. Arch Dermatol Res (2008) 0.76
Prospective validation of the "rhino conjunctivitis allergy-control-SCORE©" (RC-ACS©). Clin Transl Allergy (2012) 0.75
[New insights into fumaric acid esters (Fumaderm ®):results of the 2nd Expert Workshops]. J Dtsch Dermatol Ges (2012) 0.75
[Therapy of psoriasis vulgaris with efalizumab]. J Dtsch Dermatol Ges (2006) 0.75
Exploration of SNP variants affecting hair colour prediction in Europeans. Int J Legal Med (2015) 0.75
[Skin as manifestation organ for inflammatory rheumatic diseases]. Z Rheumatol (2013) 0.75
Treatment of actinic keratoses: why, when and how? Indian J Dermatol Venereol Leprol (2006) 0.75
Ten years of infliximab: its role in dermatology. Eur J Pharmacol (2009) 0.75
Glyceryl (mono)caprylate - a new contact allergen. Contact Dermatitis (2013) 0.75
Histomorphology and Immunophenotype of Eczematous Skin Lesions Revisited-Skin Biopsies Are Not Reliable in Differentiating Allergic Contact Dermatitis, Irritant Contact Dermatitis, and Atopic Dermatitis. Am J Dermatopathol (2017) 0.75
Refining criteria for diagnosis of cutaneous infections caused by herpes viruses through correlation of morphology with molecular pathology. Indian J Dermatol Venereol Leprol (2006) 0.75
[Therapy of psoriasis-arthritis and psoriasis vulgaris with infliximab]. J Dtsch Dermatol Ges (2006) 0.75
Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study. Dermatology (2016) 0.75
Silica gel is as effective as acyclovir cream in patients with recurrent herpes labialis: results of a randomized, open-label trial. J Dermatolog Treat (2008) 0.75
Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. J Drugs Dermatol (2017) 0.75
Dr. Kurt und Eva Herrmann-Stipendium in Höhe von 10 000 Euro für junge Dermatologinnen/Dermatologen. J Dtsch Dermatol Ges (2016) 0.75
Evidence-based (S3) guideline for the treatment of psoriasis vulgaris - Update: "Therapeutic options" and "Efalizumab". J Dtsch Dermatol Ges (2010) 0.75
[Statement of the DDG and the BVDD on the EMEA recommendations the use of raptiva [efalizumab]]. J Dtsch Dermatol Ges (2009) 0.75
Dermatological rehabilitation. J Dtsch Dermatol Ges (2011) 0.75
Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS). J Dtsch Dermatol Ges (2013) 0.75
Successful therapy of annular elastolytic giant cell granuloma with fumaric acid esters. Dermatology (2002) 0.75